Key Points
- InspireMD director Paul Stuka bought 20,000 shares on May 27 at an average price of $0.88, spending $17,600. The purchase increased his holdings to 667,871 shares, a 3.09% boost in his position.
- Stuka has been actively accumulating shares in recent weeks, with several additional purchases in early May at prices ranging from $1.12 to $1.19 per share.
- Despite the insider buying, InspireMD’s stock remains under pressure, trading near its 52-week low of $0.86 and below key moving averages; analysts still maintain a Buy consensus with an average price target of $4.50.
InspireMD, Inc. (NYSE:NSPR - Get Free Report) Director Paul Stuka acquired 20,000 shares of the stock in a transaction dated Wednesday, May 27th. The stock was acquired at an average cost of $0.88 per share, with a total value of $17,600.00. Following the purchase, the director owned 667,871 shares of the company's stock, valued at approximately $587,726.48. This trade represents a 3.09% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Paul Stuka also recently made the following trade(s):
- On Monday, May 11th, Paul Stuka acquired 10,000 shares of InspireMD stock. The stock was acquired at an average cost of $1.19 per share, with a total value of $11,900.00.
- On Friday, May 8th, Paul Stuka acquired 65,626 shares of InspireMD stock. The stock was acquired at an average cost of $1.16 per share, with a total value of $76,126.16.
- On Thursday, May 7th, Paul Stuka acquired 6,378 shares of InspireMD stock. The stock was acquired at an average cost of $1.15 per share, with a total value of $7,334.70.
- On Wednesday, May 6th, Paul Stuka acquired 1,517 shares of InspireMD stock. The stock was acquired at an average cost of $1.12 per share, with a total value of $1,699.04.
InspireMD Stock Performance
NYSE NSPR opened at $0.92 on Friday. The firm has a 50 day simple moving average of $1.30 and a 200-day simple moving average of $1.62. InspireMD, Inc. has a one year low of $0.86 and a one year high of $2.93. The firm has a market cap of $43.12 million, a price-to-earnings ratio of -1.23 and a beta of 0.82.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on NSPR shares. Loop Capital set a $5.00 price objective on shares of InspireMD in a research note on Tuesday, February 24th. Maxim Group began coverage on shares of InspireMD in a report on Monday, February 2nd. They issued a "buy" rating and a $6.00 target price on the stock. Lake Street Capital set a $4.00 target price on shares of InspireMD in a report on Monday, May 4th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $3.00 target price (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $4.50.
Read Our Latest Stock Analysis on InspireMD
Institutional Trading of InspireMD
Several hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new stake in InspireMD in the first quarter valued at approximately $29,000. Virtu Financial LLC acquired a new stake in InspireMD in the fourth quarter valued at approximately $31,000. XTX Topco Ltd acquired a new stake in InspireMD in the fourth quarter valued at approximately $30,000. Orbimed Advisors LLC raised its holdings in InspireMD by 46.9% in the fourth quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company's stock valued at $5,577,000 after acquiring an additional 1,000,000 shares in the last quarter. Finally, Essex Investment Management Co. LLC acquired a new stake in InspireMD in the fourth quarter valued at approximately $203,000. Institutional investors and hedge funds own 44.78% of the company's stock.
InspireMD Company Profile
(
Get Free Report)
InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company's core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.
The company's flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
